{"id":425029,"date":"2025-02-25T00:00:00","date_gmt":"2025-02-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0034-biopharma-post-traumatic-stress-disorder-epidemiology-epidemiology-post-traumatic-stress-disorder\/"},"modified":"2026-05-02T11:18:02","modified_gmt":"2026-05-02T11:18:02","slug":"epidcg0034-biopharma-post-traumatic-stress-disorder-epidemiology-epidemiology-post-traumatic-stress-disorder","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0034-biopharma-post-traumatic-stress-disorder-epidemiology-epidemiology-post-traumatic-stress-disorder\/","title":{"rendered":"Post-Traumatic Stress Disorder &#8211; Epidemiology &#8211; Epidemiology &#8211; Post-Traumatic Stress Disorder &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology&#8217;s coverage of post-traumatic stress disorder comprises epidemiological estimates of key patient populations across seven countries worldwide. We report the prevalence of post-traumatic stress disorder for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology&#8217;s post-traumatic stress disorder forecast will answer the following question:<\/p>\n<ul class=\"round-bullets\">\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of post-traumatic stress disorder\u00a0over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts over two patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li><abbr data-abbreviation-entity=\"5087\" title=\"post-traumatic stress disorder\">PTSD<\/abbr> total 12-months prevalence.<\/li>\n<\/ul>\n<ul class=\"round-bullets\">\n<li><abbr data-abbreviation-entity=\"5087\" title=\"post-traumatic stress disorder\">PTSD<\/abbr> total lifetime prevalence<\/li>\n<\/ul>\n<p>Note: coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-425029","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psychiatry","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/425029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/425029\/revisions"}],"predecessor-version":[{"id":425380,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/425029\/revisions\/425380"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=425029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}